Aη-α and Aη-β peptides impair LTP ex vivo within the low nanomolar range and impact neuronal activity in vivo
Open Access
- 8 July 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Alzheimer's Research & Therapy
- Vol. 13 (1), 1-13
- https://doi.org/10.1186/s13195-021-00860-1
Abstract
Amyloid precursor protein (APP) processing is central to Alzheimer’s disease (AD) etiology. As early cognitive alterations in AD are strongly correlated to abnormal information processing due to increasing synaptic impairment, it is crucial to characterize how peptides generated through APP cleavage modulate synapse function. We previously described a novel APP processing pathway producing η-secretase-derived peptides (Aη) and revealed that Aη–α, the longest form of Aη produced by η-secretase and α-secretase cleavage, impaired hippocampal long-term potentiation (LTP) ex vivo and neuronal activity in vivo. With the intention of going beyond this initial observation, we performed a comprehensive analysis to further characterize the effects of both Aη-α and the shorter Aη-β peptide on hippocampus function using ex vivo field electrophysiology, in vivo multiphoton calcium imaging, and in vivo electrophysiology. We demonstrate that both synthetic peptides acutely impair LTP at low nanomolar concentrations ex vivo and reveal the N-terminus to be a primary site of activity. We further show that Aη-β, like Aη–α, inhibits neuronal activity in vivo and provide confirmation of LTP impairment by Aη–α in vivo. These results provide novel insights into the functional role of the recently discovered η-secretase-derived products and suggest that Aη peptides represent important, pathophysiologically relevant, modulators of hippocampal network activity, with profound implications for APP-targeting therapeutic strategies in AD.Keywords
Funding Information
- Agence Nationale de la Recherche (ANR-11-LABX-0028-01)
- Fondation Plan Alzheimer
- Association France Alzheimer (AAP SM 2018 number 1795)
- Deutsche Forschungsgemeinschaft (EXC 2145 SyNergy)
- Alzheimer Forschung Initiative (15038)
- UKRI Future Leaders Fellowship (MR/S017003/1)
- BrightFocus Foundation (A2019112S)
- Agence Nationale de la Recherche (ANR-15-IDEX-01, ANR-19-HBPR-0004-02-MILEDI)
This publication has 29 references indexed in Scilit:
- Critical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of Alzheimer’s diseaseProceedings of the National Academy of Sciences of the United States of America, 2012
- Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake CycleScience, 2009
- Soluble Oligomers of Amyloid β Protein Facilitate Hippocampal Long-Term Depression by Disrupting Neuronal Glutamate UptakeNeuron, 2009
- Picomolar Amyloid-β Positively Modulates Synaptic Plasticity and Memory in HippocampusJournal of Neuroscience, 2008
- Endogenous secreted amyloid precursor protein-α regulates hippocampal NMDA receptor function, long-term potentiation and spatial memoryNeurobiology of Disease, 2008
- Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memoryNature Medicine, 2008
- Endocytosis Is Required for Synaptic Activity-Dependent Release of Amyloid-β In VivoNeuron, 2008
- The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's diseaseNeuroscience Letters, 2007
- Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In VivoNeuron, 2005
- Alzheimer's Disease Is a Synaptic FailureScience, 2002